Xvivo Perfusion ABXVIPF -1.32%91 Market Cap is $826.68 Mil as of Jun. 26, 2026. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 866 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks better than 78.06% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Xvivo Perfusion AB's share price for the quarter that ended in Mar. 2026 was $22.8108. Xvivo Perfusion AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 31.50 Mil. Therefore, Xvivo Perfusion AB's market cap for the quarter that ended in Mar. 2026 was $718.52 Mil.
Xvivo Perfusion AB's quarterly market cap
increased
from Sep. 2025 ($600.13 Mil) to Dec. 2025 ($652.03 Mil) and
increased
from Dec. 2025 ($652.03 Mil) to Mar. 2026 ($718.52 Mil).
Xvivo Perfusion AB's annual market cap
increased
from Dec. 2023 ($718.18 Mil) to Dec. 2024 ($1,294.61 Mil) but then
declined
from Dec. 2024 ($1,294.61 Mil) to Dec. 2025 ($652.03 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Xvivo Perfusion AB's Enterprise Value for Today is $807.68 Mil.
Xvivo Perfusion AB (OTCPK:XVIPF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Xvivo Perfusion AB Market Cap Related Terms
Xvivo Perfusion AB Market Cap Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Xvivo Perfusion AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Xvivo Perfusion AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB (XVIPF) has a Market Cap of $826.68 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Xvivo Perfusion AB and its competitors. According to the industry distribution chart, Xvivo Perfusion AB ranks #190 out of 866 companies in the Medical Devices & Instruments industry, placing it in the top 21.9%.
Is Xvivo Perfusion AB's Market Cap too high?
Xvivo Perfusion AB's current Market Cap is $826.68 Mil. The Medical Devices & Instruments industry median Market Cap is 121.29. Xvivo Perfusion AB's value of $826.68 Mil is 581.6% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #190 out of 866 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #190 out of 866 companies for Market Cap. This places Xvivo Perfusion AB in the top 22% of its industry — outperforming the majority of peers. The industry median Market Cap is 121.29. Xvivo Perfusion AB's value of $826.68 Mil is 581.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 121.29, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current Market Cap of $826.68 Mil is 581.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 121.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Market Cap is $826.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.07, compared to a current price of $29.00 — trading 31.1% below its estimated fair value. The current Market Cap is $826.68 Mil and 581.6% above the Medical Devices & Instruments industry median of 121.29. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Market Cap is $826.68 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 31.1% below its estimated GF Value™ of $42.07.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Market Cap: $826.68 Mil
GF Value™: $42.07 vs. price of $29.00 (31.1% below fair value)
Industry Position: 581.6% above the Medical Devices & Instruments median (#190 of 866)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
